Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20814066 | 1.00 | ENPP1 (0.69) | ENPP1MAPK7 | |
| SCHEMBL20813634 | 1.00 | ENPP1 (0.69) | ENPP1MAPK7 | |
| SCHEMBL25672756 | 0.94 | ENPP1 (0.60) | ENPP1MAPK7 | |
| SCHEMBL20798117 | 0.87 | ENPP1 (0.53) | ENPP1MAPK7 | |
| SCHEMBL29277814 | 0.86 | ENPP1 (0.52) | ENPP1MAPK7 | |
| SCHEMBL25841372 | 0.85 | ENPP1 (0.49) | ENPP1MAPK7 | |
| SCHEMBL25841370 | 0.85 | ENPP1 (0.49) | ENPP1MAPK7 | |
| SCHEMBL20797981 | 0.85 | MAPK7 (0.52) | ENPP1MAPK7 | |
| SCHEMBL30776980 | 0.85 | MAPK7 (0.52) | ENPP1MAPK7 | |
| SCHEMBL20798023 | 0.84 | MAPK7 (0.50) | ENPP1MAPK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099493-A1 | PHOSPHONATES AS INHIBITORS OF ENPP1 AND CDNP | STINGRAY THERAPEUTICS INC (US) | 2025-03-27 | — | — | US | disclosed |
| EP-4327882-A2 | ENPP1 INHIBITORS AND THEIR USE FOR THE TREATMENT OF CANCER | The Board of Trustees of the Leland Stanford Junior University (US) | 2024-02-28 | — | — | EP | disclosed |
| US-20230277570-A1 | ENPP1 Inhibitors and Their Use for the Treatment of Cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2023-09-07 | — | — | US | disclosed |
| US-11707471-B2 | ENPP1 inhibitors and their use for the treatment of cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-07-25 | — | — | US | disclosed |
| US-11701371-B2 | ENPP1 inhibitors and their use for the treatment of cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-07-18 | — | — | US | disclosed |
| US-20210369747-A1 | ENPP1 Inhibitors and Their Use for the Treatment of Cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2021-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11701371-B2 | ENPP1 inhibitors and their use for the treatment of cancer | ENPP1, ENPP3, ENTPD1 | ENPP1 1/4885MAPK7 2143/4885 |
| US-20250099493-A1 | PHOSPHONATES AS INHIBITORS OF ENPP1 AND CDNP | ENPP1, ENPP3, PPP1R1B | ENPP1 1/4885MAPK7 1040/4885 |
| US-20210369747-A1 | ENPP1 Inhibitors and Their Use for the Treatment of Cancer | ENPP1, ENPP3, ENTPD1 | ENPP1 1/4885MAPK7 2143/4885 |
| US-11707471-B2 | ENPP1 inhibitors and their use for the treatment of cancer | ENPP1, ENPP3, ENTPD1 | ENPP1 1/4885MAPK7 2143/4885 |
| US-20230277570-A1 | ENPP1 Inhibitors and Their Use for the Treatment of Cancer | ENPP1, ENPP3, ENTPD1 | ENPP1 1/4885MAPK7 2143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.